Survodutide
BI 456906 · Dual GLP-1/glucagon agonist
Think of it as a double-duty metabolic booster.
Survodutide is like a two-in-one tool for your metabolism. It combines the appetite-curbing effects of GLP-1 with the energy-boosting power of glucagon. Imagine if your body had a switch that not only told you to eat less but also encouraged it to burn more energy and fat. That's what Survodutide aims to do.
In research settings, it's shown promise for helping people lose weight—think of nearly 15% of body weight in some cases—and improve liver health in conditions tied to metabolic issues. It also helps keep blood sugar levels in check, similar to other well-known appetite suppressants.
It's still under investigation, so it's not something you can pick up at your local pharmacy just yet. But the dual-action approach has earned it some attention from researchers looking to tackle complex metabolic challenges.
Who it's for
- People aiming for significant weight loss with medical supervision
- Those managing complex metabolic issues with a healthcare provider
- Individuals interested in cutting-edge metabolic research
Probably not for you if…
- Casual dieters looking for a quick fix
- Anyone without access to medical supervision
- Individuals uncomfortable with injectable treatments
Editorial summary for research context · Not medical advice
Mechanism of Action
Survodutide is an investigational once-weekly dual agonist of the GLP-1 and glucagon receptors developed by Boehringer Ingelheim and Zealand Pharma. GLP-1 activity provides appetite suppression, delayed gastric emptying, and glucose-dependent insulinotropic effects; glucagon receptor activity is intended to drive increased energy expenditure and hepatic lipid oxidation. Granted FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis). Investigational — only pharmaceutical-grade product under clinical supervision is appropriate for human use.
Researched Benefits
Weight reduction
Phase 2 trial in adults with obesity reported mean weight loss of ~14.9% at the 4.8mg weekly dose over 46 weeks.
- [le Roux et al. 2024]
MASH resolution
Phase 2 MASH trial reported histologically-confirmed MASH improvement in 83% of participants at the top dose at 48 weeks.
- [Sanyal et al. 2024]
Glycemic control
Phase 2 T2D studies showed HbA1c reductions comparable to best-in-class GLP-1 agonists.
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Clinical titration (investigational — prescription required)
- Dosage
- 0.3 mg
- Frequency
- once weekly
- Timing
- same day each week
- Cycle
- 2 weeks
Phase 2/3 trials titrate every 2 weeks through 0.3, 0.9, 1.8, 2.7, 3.6, and 4.8mg weekly. Investigational only — no approved formulation exists.
Reported Side Effects
- Gastrointestinal: nausea, vomiting, diarrhea, constipation (dose-dependent)
- Injection-site reactions
- Transient heart rate elevation
- Decreased appetite and early satiety
- Rare: pancreatitis signals reported in trials
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy and lactation
- History of pancreatitis
Stacking Partners
Peptides commonly paired with Survodutide in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for Survodutide. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Stacks well with
· Supplement companions — independent evidence, not sponsoredLMNT Electrolyte Drink Mix Variety Pack (30 sticks)
LMNT
GLP-1 agonism suppresses thirst — dehydration + electrolyte drop is the #1 source of the 'GLP-1 flu' complaint. LMNT targets that gap directly.
Psyllium Husk Fiber Capsules (500 ct)
NOW Foods
Constipation is the most-reported GLP-1 side effect. Daily soluble fiber addresses it without blunting the appetite effect.
Whey Protein Isolate 5 lb (Grass-Fed, Unflavored)
NAKED Nutrition
Appetite suppression tanks protein intake if you don't actively defend it — protein powder is the cheapest floor against lean-mass loss.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
4:09Cirrhosis of the liver: Diet and nutrition | Ohio State Medical Center
Ohio State Wexner Medical Center
259.1K views · 4:09 · 7 years ago
5:49How To Easily & Accurately Reconstitute Your Peptides (10mg Vial Used in Example)
Coach Phil
81.2K views · 5:49 · 8 months ago
12:58Retatrutide Optimal Dosage Ranges and Glucagon Receptor Myth
Hack Smith
64.2K views · 12:58 · 9 months ago
18:49Does Ozempic Cause Hair Loss? Dermatologist Dr. Dray Weighs In
Dr Dray
36.5K views · 18:49 · 3 years ago
16:02Muscle Loss with Ozempic, Wegovy and Mounjaro?? | Dr. Dan | Obesity Expert
Dr. Dan | Obesity Expert
23.3K views · 16:02 · 2 years ago
Research Papers
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, et al. · The Lancet Diabetes & Endocrinology · 2024
PubMed 38554713 →